You have full text access to this OnlineOpen article

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients

  1. Kostas Zervas1,
  2. Evgenia Verrou1,
  3. Zisis Teleioudis1,
  4. Konstantinos Vahtsevanos2,
  5. Anastasia Banti1,
  6. Dimitra Mihou1,
  7. Dimitris Krikelis1,
  8. Evangelos Terpos3,4

Article first published online: 1 AUG 2006

DOI: 10.1111/j.1365-2141.2006.06230.x

Issue

British Journal of Haematology

British Journal of Haematology

Volume 134, Issue 6, pages 620–623, September 2006

Additional Information

How to Cite

Zervas, K., Verrou, E., Teleioudis, Z., Vahtsevanos, K., Banti, A., Mihou, D., Krikelis, D. and Terpos, E. (2006), Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology, 134: 620–623. doi: 10.1111/j.1365-2141.2006.06230.x

Author Information

  1. 1

    Departments of Haematology/Oncology

  2. 2

    Oral and Maxillofacial Surgery, ‘‘Theagenion’’ Cancer Centre, Thessaloniki

  3. 3

    Department of Haematology and Medical Research, General Airforce Hospital, Athens, Greece

  4. 4

    Department of Haematology, Faculty of Medicine, Imperial College London, London, UK

*Evangelos Terpos, Department of Haematology and Medical Research, 251 General Airforce Hospital, 3 Kanellopoulou street, GR-11525, Athens, Greece. E-mail: eterpos@hotmail.com; e.terpos@imperial.ac.uk

Publication History

  1. Issue published online: 18 AUG 2006
  2. Article first published online: 1 AUG 2006
  3. Received 27 April 2006; accepted for publication 7 June 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (572K)

Keywords:

  • multiple myeloma;
  • osteonecrosis of the jaw;
  • bisphosphonates;
  • pamidronate;
  • zoledronic acid

Summary

The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only patients who received bisphosphonates developed ONJ (28/254; 11%). Zoledronic acid produced 9·5-fold greater risk for developing ONJ than pamidronate alone (P = 0·042) and 4·5-fold greater risk than subsequent use of pamidronate + zoledronic acid (P = 0·018). Use of thalidomide and number of bisphosphonate infusions also increased the risk for ONJ by 2·4-fold (P = 0·043), and 4·9-fold respectively (P = 0·012). ONJ developed earlier among patients receiving zoledronic acid. Our data indicates that administration of zoledronic acid for more than 2 years or in combination with thalidomide requires caution in myeloma.

View Full Article (HTML) Get PDF (572K)